MarketCap
Facebook
X
Telegram
Brickell Biotech Balance Sheet 2023-2008 | BBI
Brief overview of Brickell Biotech's balance sheet structure
The review uses the five latest available annual reports between 2016 and 2021.
Across five reporting periods, assets decreased -43.2%, from $52.3 million to $29.7 million, producing a negative trend.
Liabilities grew faster than assets: -32.7% versus -43.2%. A substantial part of expansion was externally funded.
Equity accounts for 83.8% of assets. Against the initial 86.3%, the capital position looks resilient.
The cash reserve occupies 90.5% of the balance sheet, previously 9.7%. It is one marker of short-term resilience.
Retained earnings remain negative at -$145.4 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Brickell Biotech's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -29.9 M | -7.08 M | -7.23 M | -24.8 M | -5.07 M | -13.4 M | -20.5 M | -38.8 M | -43.2 M | -38.7 M | - | - | - |
Long Term Debt |
- | - | - | 146 K | 73 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 49 K | 69 K | 74 K | 78 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 146 K | 73 K | - | - | - | 359 K | 856 K | 1.29 M | 1.66 M | 1.96 M | - | - | - |
Total Current Liabilities |
1.66 M | 3.08 M | 4.81 M | 6.35 M | 10.5 M | 20.1 M | 16.9 M | 7.14 M | 4.16 M | 5.2 M | 3.65 M | 5.78 M | 6.46 M | 6.33 M | - | - |
Total Liabilities |
- | - | 4.81 M | 6.5 M | 10.6 M | 22.1 M | 16.9 M | 7.14 M | 4.52 M | 6.06 M | 4.94 M | 7.44 M | 8.42 M | - | - | - |
Deferred Revenue |
- | - | - | - | 1.8 M | 8.12 M | 11.7 M | 3.02 M | 250 K | - | 150 K | 150 K | 99 K | - | - | - |
Retained Earnings |
-172 M | -166 M | -145 M | -106 M | -85 M | -71.6 M | -427 M | -414 M | -405 M | -396 M | -379 M | -348 M | -325 M | -318 M | - | - |
Total Assets |
11.6 M | 10.3 M | 29.7 M | 33.6 M | 18.1 M | 8.75 M | 80.5 M | 52.3 M | 49.9 M | 58 M | 66.4 M | 96.5 M | 68.8 M | 72.9 M | - | - |
Cash and Cash Equivalents |
10.9 M | 8.68 M | 26.9 M | 30.1 M | 7.23 M | 8.07 M | 24.8 M | 5.07 M | 13.4 M | 20.5 M | 38.8 M | 43.2 M | 38.7 M | 47.3 M | 25.9 M | 23.8 M |
Book Value |
11.6 M | 10.3 M | 24.9 M | 27.1 M | 7.57 M | -13.3 M | 63.6 M | 45.1 M | 45.4 M | 51.9 M | 61.4 M | 89.1 M | 60.3 M | 72.9 M | - | - |
Total Shareholders Equity |
9.93 M | 7.19 M | 24.9 M | 27.1 M | 7.57 M | -71.6 M | -59.9 M | 45.1 M | 45.4 M | 51.9 M | 61.4 M | 89.1 M | 60.3 M | 64.4 M | 55 M | 48.6 M |
All numbers in USD currency
Quarterly Balance Sheet Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | 18 K | 36 K | - | - | 7 K | 31 K | 53 K | 73 K | 94 K | 73 K | 73 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | 4.81 M | 4.22 M | 6.72 M | 9.71 M | 6.5 M | 7.69 M | 7.52 M | 7.14 M | 10.6 M | 13.1 M | 10.6 M | 10.6 M | 22.1 M | 22.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | 142 K | 750 K | 1.8 M | 2.46 M | 1.8 M | 1.8 M | 8.12 M | 10 K | 20 K | 86 K | 11.7 M | 7.8 M | 7.2 M | 5.32 M | 3.02 M | 112 K | 122 K | 84 K | 250 K | 2.11 M | 520 K | 30 K | - | 38 K | 75 K | 113 K | 150 K | 37 K | 75 K | 167 K | 150 K | 99 K | 99 K | 99 K | 99 K | 99 K | 51 K | 99 K |
Retained Earnings |
-171 M | -173 M | -171 M | -166 M | -162 M | -156 M | -155 M | -145 M | -139 M | -126 M | -115 M | -106 M | -98.5 M | -94.2 M | -89.1 M | -85 M | -74.1 M | -449 M | -447 M | -71.6 M | -438 M | -437 M | -432 M | -427 M | -423 M | -420 M | -417 M | -414 M | -411 M | -409 M | -407 M | -405 M | -403 M | -402 M | -399 M | -396 M | -391 M | -387 M | -383 M | -379 M | -377 M | -367 M | -357 M | -348 M | -340 M | -333 M | -325 M | -325 M | -318 M | -335 M | -325 M |
Total Assets |
13.1 M | 9.84 M | 12 M | 10.3 M | 14.4 M | 18.5 M | 20.8 M | 29.7 M | 24.2 M | 29.1 M | 38.9 M | 33.6 M | 26.4 M | 27.4 M | 13 M | 18.1 M | 31.4 M | 42.7 M | 46.4 M | 8.75 M | 55.6 M | 56.8 M | 61.4 M | 80.5 M | 49.6 M | 50.8 M | 51.4 M | 52.3 M | 51.8 M | 45.8 M | 47.2 M | 49.9 M | 53.4 M | 52.4 M | 54.4 M | 58 M | 61.3 M | 61.6 M | 63.3 M | 66.4 M | 69.5 M | 79.3 M | 88 M | 96.5 M | 103 M | 110 M | 119 M | 68.8 M | 74 M | 56.7 M | 68.8 M |
Cash and Cash Equivalents |
12 M | 8.95 M | 10.8 M | 8.68 M | 11.2 M | 14.5 M | 17.3 M | 26.9 M | 21.4 M | 24.4 M | 34.8 M | 30.1 M | 20.2 M | 21.6 M | 7.13 M | 7.23 M | 7.22 M | 10.8 M | 11.3 M | 8.07 M | 12.1 M | 10.1 M | 10.1 M | 24.8 M | 10.2 M | 4.61 M | 4.56 M | 5.07 M | 8.46 M | 5.23 M | 5.93 M | 13.4 M | 18.7 M | 19.7 M | 17.7 M | 20.5 M | 22.7 M | 31.8 M | 40.8 M | 38.8 M | 38.8 M | 45 M | 47 M | 43.2 M | 53.2 M | 65.7 M | 70.5 M | 38.7 M | 41.1 M | 24.6 M | 38.7 M |
Book Value |
13.1 M | 9.84 M | 12 M | 10.3 M | 14.4 M | 18.5 M | 20.8 M | 24.9 M | 20 M | 22.4 M | 29.1 M | 27.1 M | 18.7 M | 19.9 M | 5.89 M | 7.57 M | 18.2 M | 32.1 M | 35.9 M | -13.3 M | 33.6 M | 56.8 M | 61.4 M | 80.5 M | 49.6 M | 50.8 M | 51.4 M | 52.3 M | 51.8 M | 45.8 M | 47.2 M | 49.9 M | 53.4 M | 52.4 M | 54.4 M | 58 M | 61.3 M | 61.6 M | 63.3 M | 66.4 M | 69.5 M | 79.3 M | 88 M | 96.5 M | 103 M | 110 M | 119 M | 68.8 M | 74 M | 56.7 M | 68.8 M |
Total Shareholders Equity |
10.9 M | 7.99 M | 9.87 M | 7.19 M | 11.2 M | 15.6 M | 16 M | 24.9 M | 20 M | 22.4 M | 29.1 M | 27.1 M | 18.7 M | 19.9 M | 5.89 M | 7.57 M | 18.2 M | 41.5 M | 43.9 M | -71.6 M | 52.1 M | 53.6 M | 58.2 M | -59.9 M | 37.7 M | 39.8 M | 42.6 M | 45.1 M | 47.9 M | 42.4 M | 43.4 M | 45.4 M | 47.5 M | 47.2 M | 49.5 M | 51.9 M | 55.7 M | 56.7 M | 58.7 M | 61.4 M | 62.9 M | 71.7 M | 81.2 M | 89.1 M | 96 M | 103 M | 110 M | 60.3 M | 66.5 M | 48.9 M | 60.3 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Brickell Biotech, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
